“The beginning of a paradigm shift within pathology”
STOCKHOLM – June 20, 2023 – Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology, announces the opening of its first laboratory, having delivered its first prostate cancer diagnoses.
“We are extremely proud to have launched successfully and according to plan. We have now started to deliver our unique diagnostic services to our first customers here in Sweden,” says Fredrik Palm, CEO at Inify Laboratories.
The company offers specialized pathology diagnostics for prostate cancer, the second most common cancer among men in the Western world. It clearly targets present and growing challenges. Variation in diagnostic quality and long, unpredictable waiting times increase the cost and workload for public and private clinics, while creating great anxiety for patients. Inify’s laboratory and logistic services has the capacity to provide the entire Nordic region with diagnostic with short, predictable response times.
State-of-the-art workflow with seamlessly integrated AI
One year after funding, being listed on the Euronext Growth in Oslo, and signing a lease for new premises, Inify has managed to build and fully equip its first ultramodern laboratory.
Its cross-professional team of software engineering, laboratory and medical experts has designed and developed a customized laboratory information system (LIS), which includes optimized tissue preparation processes and seamless integration of its state-of-the-art AI. All together a unique system that supports pathologists in performing efficient and high-quality diagnosis, on every patient case.
“Our vision is to provide world-leading cancer diagnostics for as many patients as possible. This launch is the beginning of a paradigm shift within clinical pathology, delivering real value for healthcare providers and patients,” says Dr Claes Lindh, Chief Medical Officer at Inify Laboratories.
Aiming to set new diagnostic standards
Prior to the opening, Inify entered a partnership with the Swedish branch of Loomis, a value transport company with a multinational presence. The partnership guarantees traceable and efficient patient sample transportation from clinics to Inify Laboratories. The logistic service has full coverage in Sweden, and can be easily extended to cover transportation from and within other countries, facilitating future international expansion.
“Our greatest success factor is our dedicated and innovative cross-professional team, which includes every single employee as well as the members of the board. We aim to set new diagnostic standards for selected cancer types together with public and private healthcare providers, and to generate continuously growing shareholder value,” says Palm.
For further information, please contact CEO, Fredrik Palm, , or visit www.inify.com.
About Inify Laboratories
Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI- supported workflow to optimize quality and response times, initially within prostate. The concept is scalable and can be extended to other diagnoses.
The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer’s organization. The report is assisted by our own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system.
The company, based in Sweden, became independent in 2022 through a spin-off from ContextVision, with 40 years of experience within digital imaging for medical applications. It is listed on Euronext Growth Oslo under the ticker INIFY.
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
Attachment
View attachment